Storage, preparation and dispensing of solutions.
Some examples of diagnostic and drug discovery reagents require preparation prior to use. For instance, reagents may require measuring a solution and using the solution to rehydrate dry reagent. In other examples, preparation of the reagent requires measuring and mixing of a sample solution with a reagent in a dried or liquid form. In still other examples, preparation of the reagent requires mixing of two or more liquid components, such as a reagent and a solution.
Manufacturers of diagnostic and drug discovery reagents use precision and standardized procedures in order to produce high quality reagents. These reagents are then prepared at their point of use. The quality of the reagents (e.g., the precise amount of reagent solution, the purity of the reagent solution and the like) is easily compromised at the point of use because of errors in preparation procedures that are used by personnel responsible for preparing the reagent. For instance, the reagent is handled in an unclean environment having contaminants (e.g., humid atmosphere, biologically active environment, chemically active environment, and the like), the wrong amount of solution is used, the wrong solution is used, and the like. In other examples, the reagent and solution are not allowed to mix thoroughly. In still other examples, the reagent solution is dispensed from a device but fails to deliver the full specified amount of reagent solution as a result of operator error or device performance (e.g., a portion of the solution is left within the device, more or less than a single aliquot of solutions is formed).
Where lyophilized reagents (e.g., dried or freeze-dried reagents) are used, unwanted exposure to contaminants including, but not limited to, moisture or moisture vapor during storage and prior to reconstitution may contaminate or compromise the stability of the lyophilized reagent. Compromising the reagent decreases its ability to rapidly rehydrate thereby creating difficulties in preparing a reagent at the proper concentration.
Even small errors in preparation leading to an improperly prepared reagent may have undesirable consequences, including, but not limited to, false positives, inaccurate diagnoses leading to inaccurate or inappropriate treatments, and false negatives (undetected diagnoses resulting in no treatment where treatment is needed).
A more complete understanding of the present subject matter may be derived by referring to the detailed description and claims when considered in connection with the following illustrative Figures. In the following Figures, like reference numbers refer to similar elements and steps throughout the Figures.
Elements and steps in the Figures are illustrated for simplicity and clarity and have not necessarily been rendered according to any particular sequence. For example, steps that may be performed concurrently or in different order are illustrated in the Figures to help to improve understanding of examples of the present subject matter.
In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific examples in which the subject matter may be practiced. These examples are described in sufficient detail to enable those skilled in the art to practice the subject matter, and it is to be understood that other examples may be utilized and that structural changes may be made without departing from the scope of the present subject matter. Therefore, the following detailed description is not to be taken in a limiting sense, and the scope of the present subject matter is defined by the appended claims and their equivalents.
While the devices and methods presented in the detailed description describe devices for non-therapeutic uses, non-pharmaceutical uses and the like, the devices and methods are applicable to at least some pharmaceutical applications that do not require administration to a subject by injection with a syringe needle. It is also within the scope of the devices and methods described herein that a syringe needle and medicaments are usable with the same. For instance, the access port includes a self-sealing septum. Additionally, the reagents described below include, but are not limited to, lyophilized reagents, liquid reagents, powder reagents and the like. Further, the solutions described below include, but are not limited to, liquid solutions such as, saline, distilled water, tap water, pH buffered water, chemical solutions capable of breaking down the reagents and the like. In another example, the solutions include, but are not limited to, biological or environmental samples in a liquid form or suspended within a liquid, such as blood, urine, fecal matter, saliva, perspiration, soil, ground water, fresh water, salt water, explosives, explosive residues, toxins and the like.
Referring now to
Referring now to
The reagent preparation assembly 100 includes the reaction chamber 410 positioned beneath the body 102. In one example, the body 102 includes the structural housing of the assembly 100 including the reaction chamber 410. The gasket 420 is interposed between the body 102 and the reaction chamber 410. In one example, the cap 108 is crimped at a crimp 422 around the body 102, gasket 420 and the reaction chamber 410. The crimp 422 tightly engages the body, gasket and the reaction chamber 410 and substantially prevents the ingress of moisture and atmosphere into the reaction chamber 410 containing a reagent 408. In another example a desiccant 430 is held within the cap 108 to absorb moisture within the cap.
In the example shown in
Referring again to the reaction chamber 410, in the example shown in
Referring now to
As shown in
In the example shown in
Referring now to
Referring now to
As shown, the syringe 400 fills a portion of the reaction chamber 410 thereby limiting the space devoted to reconstitution of the reagent 408 with the solution 406. Reconstitution is thereby localized within a well of the reaction chamber 410 directly or substantially underlying the access port 106 to facilitate easy drawing of the reagent mixture into an instrument such as a pipette when positioned within the access port 106. The tapered surface 428 (e.g., beveled edge) further diverts the reagent mixture to the well portion of the reaction chamber 410 to retain the mixture until withdrawn by an instrument.
As previously described, as the piston 402 moves the solution 406 into the reaction chamber 410 gas is displaced from the reaction chamber 410. The gas travels through the vent path 506 and out the access port 106 (e.g., exterior to the assembly 100) to equalize pressure within the reaction chamber 410 and thereby substantially prevent any likelihood of premature opening of the access seal 418. Optionally, the reagent preparation assembly 100 is without a vent path 506 and pressure is allowed to buildup within the reaction chamber 410. In one example, where the assembly 100 is without a vent path 506 the overpressure is minimal and not strong enough to break the access seal 418. In yet another example, a hydrophobic membrane elsewhere on the reaction chamber 410 or body 102 allows for the passage of gas from the reaction chamber and prevents the passage of the solution or reagent mixture.
Referring first to
The tapering reaction chamber 902 forms a well 908 that tapers toward a trough 910 positioned substantially beneath the access port 106. As previously described, tapering the well toward the area underneath the access port 106 facilitates delivery of an instrument tip such as a pipette tip to the bottom of the well 908 to ensure drawing of substantially all or a portion of the reagent mixture formed within the reaction chamber 902. As shown in
Referring now to
The reagent preparation assembly 900 further includes a vent path 914 shown in
The reagent preparation assemblies described herein provide storage and reconstitution assemblies that are easy to use for a variety of diagnostic, life science research and testing purposes. Each assembly includes a specified amount of solution to mx with the loaded reagent (or reagents). The solution and reagent held in separate reservoirs and isolated until reconstitution is desired. The assemblies are storable for long periods of time and immediately usable. Additionally, because the assemblies include measured amounts of solution that reconstitute the reagent (or reagents) without leaving excess solution, a reagent solution having a specified concentration is consistently formed. Multiple aliquots, for instance 5 or more, are created at a desired time for immediate use without retaining or generating large volumes of a reagent mixture and storing the same. The attendant issues of storing larger volumes of a reagent mixture are thereby avoided including, spoilage, dilution, contamination and the like.
The all-in-one assemblies places the solution, the reagent, the mixing device and an access port in a single housing and thereby substantially eliminates user based variables that may negatively impact the quality and function of a reagent. The assemblies eliminate many measuring and handling steps so that high level manufacturing quality standards for the reagent are carried forward and maintained during preparation of the reagent. Proper preparation of the reagent with the assemblies described herein is thereby not dependent on the skill, experience, competency or technique of the user. Having the specified amount (one or more aliquots) and concentration of the reagent mixture ensures a testing or diagnostic scheme is accurately performed and provides the technician with a confident diagnostic or test result.
Further, the tapered well of the assemblies substantially ensures the solution and the reagent mix in a localized area within the reaction chamber. Moreover, the reagent mixture is retained substantially beneath the access port to ensure instruments extending into the reaction chamber have ready access to the mixture. Pooling or spreading of the reagent mixture in disparate areas of the reaction chamber is thereby avoided. Moreover, the positioning of the syringe within the reaction chamber partially fills the reaction chamber and further minimizes the displacement of the reagent mixture from the trough of the well. A technician is thereby able to readily and accurately withdraw each of the one or more doses from the reaction chamber with little or no portion of the reagent mixture retained in an inaccessible portion of the chamber.
The example assemblies described above include diagnostic and testing solutions and reagents. Each of the assemblies previously described and claimed herein is similarly applicable for use in therapeutic and pharmaceutical applications, such as drug reconstitution, administration and the like. To the extent reagents, mixtures and preparation assemblies are described and claimed herein, therapeutic and pharmaceutical reagents, mixtures and devices are similarly considered within the scope of the description, figures and the claims.
In the foregoing description, the subject matter has been described with reference to specific exemplary examples. However, it will be appreciated that various modifications and changes may be made without departing from the scope of the present subject matter as set forth herein. The description and figures are to be regarded in an illustrative manner, rather than a restrictive one and all such modifications are intended to be included within the scope of the present subject matter. Accordingly, the scope of the subject matter should be determined by the generic examples described herein and their legal equivalents rather than by merely the specific examples described above. For example, the steps recited in any method or process example may be executed in any order and are not limited to the explicit order presented in the specific examples. Additionally, the components and/or elements recited in any apparatus example may be assembled or otherwise operationally configured in a variety of permutations to produce substantially the same result as the present subject matter and are accordingly not limited to the specific configuration recited in the specific examples.
Benefits, other advantages and solutions to problems have been described above with regard to particular examples; however, any benefit, advantage, solution to problems or any element that may cause any particular benefit, advantage or solution to occur or to become more pronounced are not to be construed as critical, required or essential features or components.
As used herein, the terms “comprises”, “comprising”, or any variation thereof, are intended to reference a non-exclusive inclusion, such that a process, method, article, composition or apparatus that comprises a list of elements does not include only those elements recited, but may also include other elements not expressly listed or inherent to such process, method, article, composition or apparatus. Other combinations and/or modifications of the above-described structures, arrangements, applications, proportions, elements, materials or components used in the practice of the present subject matter, in addition to those not specifically recited, may be varied or otherwise particularly adapted to specific environments, manufacturing specifications, design parameters or other operating requirements without departing from the general principles of the same.
The present subject matter has been described above with reference to examples. However, changes and modifications may be made to the examples without departing from the scope of the present subject matter. These and other changes or modifications are intended to be included within the scope of the present subject matter, as expressed in the following claims.
It is to be understood that the above description is intended to be illustrative, and not restrictive. Many other examples will be apparent to those of skill in the art upon reading and understanding the above description. It should be noted that examples discussed in different portions of the description or referred to in different drawings can be combined to form additional examples of the present application. The scope of the subject matter should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
This patent application is a continuation of U.S. patent application Ser. No. 16/524,922, filed on Jul. 29, 2019, which is a continuation of U.S. patent application Ser. No. 14/597,677, filed on Jan. 15, 2015, which is a continuation of U.S. patent application Ser. No. 13/805,166, filed on Apr. 5, 2013 which is a national stage application under 35 U.S.C. § 371 of PCT/US2011/042443, filed Jun. 29, 2011, and published as WO 2012/006185 A1 on Jan. 12, 2012, which claims priority benefit of U.S. Provisional Patent Application Ser. No. 61/359,636 filed Jun. 29, 2010, which applications and publication are incorporated by reference as if reproduced herein and made a part hereof in their entirety, and the benefit of priority of each of which is claimed herein.
Number | Name | Date | Kind |
---|---|---|---|
2176041 | Pittenger | Oct 1939 | A |
2591706 | Lockhart | Apr 1952 | A |
3489147 | Shaw | Jan 1970 | A |
3834387 | Brown | Sep 1974 | A |
4031892 | Hurschman | Jun 1977 | A |
4226236 | Genese | Oct 1980 | A |
4515753 | Smith et al. | May 1985 | A |
4516967 | Kopfer | May 1985 | A |
4693706 | Ennis, III et al. | Sep 1987 | A |
4768568 | Fournier et al. | Sep 1988 | A |
4834149 | Fournier et al. | May 1989 | A |
4973168 | Chan | Nov 1990 | A |
5000922 | Turpen | Mar 1991 | A |
5071769 | Kundu et al. | Dec 1991 | A |
5199949 | Haber et al. | Apr 1993 | A |
5232664 | Krawzak et al. | Aug 1993 | A |
5277873 | Hsei | Jan 1994 | A |
5281198 | Haber et al. | Jan 1994 | A |
5449494 | Seeney | Sep 1995 | A |
5605542 | Tanaka et al. | Feb 1997 | A |
5637087 | O'Neil et al. | Jun 1997 | A |
5704918 | Higashikawa | Jan 1998 | A |
5785682 | Grabenkort | Jul 1998 | A |
5827262 | Neftel et al. | Oct 1998 | A |
5865799 | Tanaka et al. | Feb 1999 | A |
5869003 | Nason | Feb 1999 | A |
5879635 | Nason | Mar 1999 | A |
5899881 | Grimard et al. | May 1999 | A |
5951160 | Ronk | Sep 1999 | A |
5965453 | Skiffington et al. | Oct 1999 | A |
5971953 | Bachynsky | Oct 1999 | A |
6045755 | Lebl et al. | Apr 2000 | A |
6048735 | Hessel et al. | Apr 2000 | A |
6248294 | Nason | Jun 2001 | B1 |
6284549 | Guthrie | Sep 2001 | B1 |
6406175 | Marino | Jun 2002 | B1 |
6419656 | Vetter et al. | Jul 2002 | B1 |
6481435 | Hochrainer et al. | Nov 2002 | B2 |
6488894 | Miethe et al. | Dec 2002 | B1 |
6551834 | Carpenter et al. | Apr 2003 | B2 |
6569125 | Jepson et al. | May 2003 | B2 |
6632681 | Chu | Oct 2003 | B1 |
6641561 | Hill et al. | Nov 2003 | B1 |
6656150 | Hill et al. | Dec 2003 | B2 |
6702778 | Hill et al. | Mar 2004 | B2 |
6770052 | Hill et al. | Aug 2004 | B2 |
6817987 | Vetter et al. | Nov 2004 | B2 |
6820506 | Kipke et al. | Nov 2004 | B2 |
6863866 | Kelly et al. | Mar 2005 | B2 |
6878338 | Taylor et al. | Apr 2005 | B2 |
6924498 | Feldsine et al. | Aug 2005 | B2 |
6953445 | Wilmot et al. | Oct 2005 | B2 |
6986346 | Hochrainer et al. | Jan 2006 | B2 |
7030403 | Feldsine et al. | Apr 2006 | B2 |
7040311 | Hochrainer et al. | May 2006 | B2 |
7090803 | Gould et al. | Aug 2006 | B1 |
7329235 | Bertron et al. | Feb 2008 | B2 |
7967779 | Bertron et al. | Jun 2011 | B2 |
8329119 | Pearcy et al. | Dec 2012 | B2 |
8919390 | Pearcy et al. | Dec 2014 | B2 |
8940539 | Pearcy et al. | Jan 2015 | B2 |
8973749 | Pearcy et al. | Mar 2015 | B2 |
9889442 | Pearcy et al. | Feb 2018 | B2 |
10406524 | Pearcy et al. | Sep 2019 | B2 |
10668473 | Pearcy et al. | Jun 2020 | B2 |
20010016703 | Wironen et al. | Aug 2001 | A1 |
20030039588 | Miethe et al. | Feb 2003 | A1 |
20030157564 | Smith et al. | Aug 2003 | A1 |
20030209653 | Feldsine et al. | Nov 2003 | A1 |
20030235512 | Carpenter et al. | Dec 2003 | A1 |
20040097874 | Griffiths et al. | May 2004 | A1 |
20040138611 | Griffiths et al. | Jul 2004 | A1 |
20040170533 | Chu | Sep 2004 | A1 |
20050075602 | Cherif-cheikh et al. | Apr 2005 | A1 |
20050075604 | Lee | Apr 2005 | A1 |
20060052747 | Nishimura et al. | Mar 2006 | A1 |
20060079834 | Tennican et al. | Apr 2006 | A1 |
20060116644 | Norton | Jun 2006 | A1 |
20060139631 | Feldsine et al. | Jun 2006 | A1 |
20060169348 | Yigal | Aug 2006 | A1 |
20060184103 | Paproski et al. | Aug 2006 | A1 |
20060216196 | Satoh et al. | Sep 2006 | A1 |
20070014690 | Lawrence et al. | Jan 2007 | A1 |
20080188799 | Mueller-beckhaus et al. | Aug 2008 | A1 |
20080188828 | Reynolds et al. | Aug 2008 | A1 |
20080300551 | Schiller et al. | Dec 2008 | A1 |
20090117646 | Stordeur et al. | May 2009 | A1 |
20100249753 | Gaisser et al. | Sep 2010 | A1 |
20110127294 | Pearcy et al. | Jun 2011 | A1 |
20110224610 | Lum et al. | Sep 2011 | A1 |
20110224611 | Lum et al. | Sep 2011 | A1 |
20110224612 | Lum et al. | Sep 2011 | A1 |
20120179137 | Bartlett et al. | Jul 2012 | A1 |
20120201726 | Pearcy et al. | Aug 2012 | A1 |
20130030412 | Bartlett et al. | Jan 2013 | A1 |
20130208558 | Pearcy et al. | Aug 2013 | A1 |
20140048556 | Pearcy et al. | Feb 2014 | A1 |
20140322102 | Pearcy et al. | Oct 2014 | A1 |
20150125364 | Pearcy et al. | May 2015 | A1 |
20190351420 | Pearcy et al. | Nov 2019 | A1 |
Number | Date | Country |
---|---|---|
2011276396 | Aug 2014 | AU |
2014280969 | Feb 2015 | AU |
2015202242 | Nov 2016 | AU |
2803375 | May 2016 | CA |
2724339 | Aug 2017 | CA |
2880981 | Aug 2017 | CA |
19543240 | May 1997 | DE |
1103304 | May 2001 | EP |
2405961 | Jan 2012 | EP |
2640526 | Sep 2016 | EP |
2588404 | Mar 2018 | EP |
2006271938 | Oct 2006 | JP |
WO-8603589 | Jun 1986 | WO |
WO-9103224 | Mar 1991 | WO |
WO-9210225 | Jun 1992 | WO |
WO-9517916 | Jul 1995 | WO |
WO-9630066 | Oct 1996 | WO |
WO-9703209 | Jan 1997 | WO |
WO-2009140502 | Nov 2009 | WO |
WO-2010104858 | Sep 2010 | WO |
WO-2011123762 | Oct 2011 | WO |
WO-2012006185 | Jan 2012 | WO |
WO-2012067619 | May 2012 | WO |
WO-2013043861 | Mar 2013 | WO |
WO-2013163598 | Oct 2013 | WO |
WO-2014004695 | Jan 2014 | WO |
Entry |
---|
US 8,807,178 B2, 08/2014, Pearcy (withdrawn) |
“European Application Serial No. 16190922.1, Communication Pursuant to Article 94(3) EPC dated May 29, 2020”, 4 pgs. |
“European Application Serial No. 16190922.1, Response filed Oct. 8, 2020 to Communication Pursuant to Article 94(3) EPC dated May 29, 2020”, 10 pgs. |
“European Application Serial No. 16190922.1, Communication Pursuant to Article 94(3) EPC dated Dec. 15, 2020”, 6 pgs. |
“European Application Serial No. 16190922.1, Response filed Apr. 26, 2021 to Communication Pursuant to Article 94(3) EPC dated Dec. 15, 2020”, 20 pgs. |
“U.S. Appl. No. 12/992,552, Examiner Interview Summary dated Jun. 11, 2013”, 4 pgs. |
“U.S. Appl. No. 12/992,552, Final Office Action dated Mar. 1, 2013”, 21 pgs. |
“U.S. Appl. No. 12/992,552, Non Final Office Action dated Aug. 2, 2012”, 18 pgs. |
“U.S. Appl. No. 12/992,552, Notice of Allowance dated Nov. 21, 2014”, 7 pgs. |
“U.S. Appl. No. 12/992,552, Preliminary Amendment filed Nov. 12, 2010”, 6 pgs. |
“U.S. Appl. No. 12/992,552, Response filed Jul. 1, 2013 to Final Office Action dated Mar. 1, 2013”, 23 pgs. |
“U.S. Appl. No. 12/992,552, Response filed Dec. 20, 2012 to Non Final Office Action dated Aug. 2, 2012”, 22 pgs. |
“U.S. Appl. No. 12/992,552, Supplemental Preliminary Amendment filed Dec. 13, 2010”, 9 pgs. |
“U.S. Appl. No. 13/450,365, Notice of Allowance dated Aug. 16, 2012”, 13 pgs. |
“U.S. Appl. No. 13/450,365, Preliminary Amendment filed Jul. 27, 2012”, 12 pgs. |
“U.S. Appl. No. 13/805,166, Notice of Allowability dated Jan. 23, 2015”, 2 pgs. |
“U.S. Appl. No. 13/805,166, Notice of Allowance dated Oct. 15, 2014”, 8 pgs. |
“U.S. Appl. No. 13/805,166, Preliminary Amendment filed Dec. 18, 2012”, 8 pgs. |
“U.S. Appl. No. 13/805,166, Response filed Sep. 25, 2014 to Restriction Requirement dated Jul. 22, 2014”, 14 pgs. |
“U.S. Appl. No. 13/805,166, Restriction Requirement dated Jul. 22, 2014”, 8 pgs. |
“U.S. Appl. No. 13/988,279, Notice of Allowability dated Nov. 21, 2014”, 2 pgs. |
“U.S. Appl. No. 13/988,279, Notice of Allowance dated Feb. 4, 2014”, 9 pgs. |
“U.S. Appl. No. 13/988,279, Notice of Allowance dated Apr. 1, 2014”, 8 pgs. |
“U.S. Appl. No. 13/988,279, Notice of Allowance dated Aug. 22, 2014”, 8 pgs. |
“U.S. Appl. No. 13/988,279, Preliminary Amendment filed May 17, 2013”, 9 pgs. |
“U.S. Appl. No. 13/988,279, PTO Response to Rule 312 Communication dated Jun. 30, 2014”, 2 pgs. |
“U.S. Appl. No. 14/331,431, Advisory Action dated Aug. 29, 2017”, 3 pgs. |
“U.S. Appl. No. 14/331,431, Corrected Notice of Allowance dated Jan. 11, 2018”, 5 pgs. |
“U.S. Appl. No. 14/331,431, Final Office Action dated Jul. 7, 2017”, 8 pgs. |
“U.S. Appl. No. 14/331,431, Non Final Office Action dated Dec. 20, 2016”, 8 pgs. |
“U.S. Appl. No. 14/331,431, Notice of Allowance dated Oct. 20, 2017”, 8 pgs. |
“U.S. Appl. No. 14/331,431, Preliminary Amendment filed Sep. 18, 2014”, 9 pgs. |
“U.S. Appl. No. 14/331,431, Response filed Aug. 11, 2017 to Final Office Action dated Jul. 7, 2017”, 10 pgs. |
“U.S. Appl. No. 14/331,431, Response filed Sep. 15, 2016 to Restriction Requirement dated Jul. 15, 2016”, 15 pgs. |
“U.S. Appl. No. 14/331,431, Response filed Mar. 20, 2017 to Non-Final Office Action dated Dec. 20, 2016”, 11 pgs. |
“U.S. Appl. No. 14/331,431, Restriction Requirement dated Jul. 15, 2016”, 8 pgs. |
“U.S. Appl. No. 14/597,677, Advisory Action dated Dec. 10, 2018”, 4 pgs. |
“U.S. Appl. No. 14/597,677, Ex Parte Quayle Action mailed Jan. 7, 2019”, 4 pgs. |
“U.S. Appl. No. 14/597,677, Final Office Action mailed Apr. 20, 2018”, 7 pgs. |
“U.S. Appl. No. 14/597,677, Non Final Office Action dated Nov. 27, 2017”, 7 pgs. |
“U.S. Appl. No. 14/597,677, Notice of Allowance dated Apr. 25, 2019”, 7 pgs. |
“U.S. Appl. No. 14/597,677, Pre-Appeal Brief filed Aug. 20, 2018”, 5 pgs. |
“U.S. Appl. No. 14/597,677, Preliminary Amendment filed Feb. 12, 2015”, 6 pgs. |
“U.S. Appl. No. 14/597,677, Response filed Mar. 7, 2019 to Ex Parte Quayle Action mailed Jan. 7, 2019”, 7 pgs. |
“U.S. Appl. No. 14/597,677, Response filed Mar. 27, 2018 to Non Final Office Action dated Nov. 27, 2017”, 14 pgs. |
“U.S. Appl. No. 14/597,677, Response filed Nov. 8, 2017 to Restriction Requirement dated Jul. 5, 2017”, 8 pgs. |
“U.S. Appl. No. 14/597,677, Response filed Nov. 21, 2018 to Final Office Action dated Apr. 20, 2018”, 13 pgs. |
“U.S. Appl. No. 14/597,677, Response filed Dec. 20, 2018 to Advisory Action dated Dec. 10, 2018”, 13 pgs. |
“U.S. Appl. No. 14/597,677, Restriction Requirement dated Jul. 5, 2017”, 6 pgs. |
“U.S. Appl. No. 16/524,922, Non Final Office Action dated Sep. 25, 2019”, 6 pgs. |
“U.S. Appl. No. 16/524,922, Notice of Allowance dated Jan. 23, 2020”, 5 pgs. |
“U.S. Appl. No. 16/524,922, Response filed Dec. 26, 2019 to Non Final Office Action dated Sep. 25, 2019”, 6 pgs. |
“Australian Application Serial No. 2009246306, Office Action dated Mar. 13, 2014”, 4 pgs. |
“Australian Application Serial No. 2009246306, Response filed Sep. 1, 2014 to Office Action dated Mar. 13, 2014”, 18 pgs. |
“Australian Application Serial No. 2009246306, Voluntary Amendment filed Jan. 25, 2011”, 42 pgs. |
“Australian Application Serial No. 2010363976, Amendment filed Apr. 29, 2014”, 17 pgs. |
“Australian Application Serial No. 2010363976, First Examiners Report dated Jan. 7, 2015”, 2 pgs. |
“Australian Application Serial No. 2010363976, Office Action dated May 13, 2013”, 2 pgs. |
“Australian Application Serial No. 2010363976, Response filed May 22, 2013 to Office Action dated May 13, 2013”, 58 pgs. |
“Australian Application Serial No. 2010363976, Response filed Apr. 16, 2015 to First Examiners Report dated Jan. 7, 2015”, 1 pg. |
“Australian Application Serial No. 2011276396, Notice of Acceptance dated Apr. 24, 2014”, 2 pgs. |
“Australian Application Serial No. 2011276396, Office Action dated Dec. 11, 2013”, 3 pgs. |
“Australian Application Serial No. 2011276396, Response filed Apr. 10, 2014 to Office Action dated Dec. 11, 2013”, 19 pgs. |
“Australian Application Serial No. 2011276396, Voluntary Amendment filed Dec. 17, 2012”, 14 pgs. |
“Australian Application Serial No. 2014280969, Non Final Office Action dated Jan. 12, 2015”, 2 pgs. |
“Australian Application Serial No. 2015202242, First Examiner Report dated May 10, 2016”, 3 pgs. |
“Australian Application Serial No. 2015202242, Response filed Sep. 21, 2016 to First Examiner Report dated May 10, 2016”, 26 pgs. |
“Canadian Apllication Serial No. 2,803,375 Response filed Nov. 25, 2014 to Non Final Office Action dated Jun. 5, 2014”, 3 Pgs. |
“Canadian Application Serial No. 2,724,339, Office Action dated Jun. 11, 2015”, 5 pgs. |
“Canadian Application Serial No. 2,724,339, Response filed Dec. 11, 2015 to Office Action dated Jun. 11, 2015”, (English Translation of Claims), 319 pgs. |
“Canadian Application Serial No. 2,803,375, Office Action dated Jun. 5, 2014”, 2 pgs. |
“Canadian Application Serial No. 2,880,981, Office Action dated Mar. 8, 2016”, 4 pgs. |
“Canadian Application Serial No. 2,880,981, Response filed Sep. 7, 2016 to Office Action dated Mar. 8, 2016”, 13 pgs. |
“European Application Serial No. 09747584.2, Communication Pursuant to Article 94(3) EPC dated Jul. 5, 2016”, 7 pgs. |
“European Application Serial No. 09747584.2, Communication Pursuant to Article 94(3) EPC dated Nov. 28, 2018”, 5 pgs. |
“European Application Serial No. 09747584.2, Response filed Nov. 15, 2016 to Communication Pursuant to Article 94(3) EPC dated Jul. 5, 2016”, 16 pgs. |
“European Application Serial No. 10859869.9, Examination Notification Art. 94(3) dated Jun. 23, 2015”, 4 pgs. |
“European Application Serial No. 10859869.9, Extended European Search Report dated May 20, 2014”, 7 pgs. |
“European Application Serial No. 10859869.9, Office Action dated Jul. 5, 2013”, 2 pgs. |
“European Application Serial No. 10859869.9, Response filed Jul. 19, 2013 to Office Action dated Jul. 5, 2013”, 54 pgs. |
“European Application Serial No. 10859869.9, Response filed Dec. 1, 2014 to Extended European Search Report dated May 20, 2014”, 26 pgs. |
“European Application Serial No. 10859869.9, Response filed Dec. 14, 2015 to Examination Notification Art. 94(3) dated Jun. 23, 2015”, 17 pgs. |
“European Application Serial No. 11804202.7, Communication Pursuant to Artilce 94(3) and Rule 71(1) EPC dated Mar. 16, 2017”, 5 pgs. |
“European Application Serial No. 11804202.7, Extended European Search Report dated Jul. 7, 2014”, 6 pgs. |
“European Application Serial No. 11804202.7, Office Action dated Apr. 10, 2013”, 2 pgs. |
“European Application Serial No. 11804202.7, Response filed Feb. 3, 2015 to Extended European Search Report dated Jul. 7, 2014”, 14 pgs. |
“European Application Serial No. 16190922.1, Communication Pursuant to Article 94(3) EPC dated Apr. 12, 2019”, 5 pgs. |
“European Application Serial No. 16190922.1, Extended European Search Report dated Mar. 1, 2017”, 7 pgs. |
“European Application Serial No. 16190922.1, Response filed Sep. 29, 2017 to Extended European Search Report dated Mar. 1, 2017”, 18 pgs. |
“European Application Serial No. 16190922.1, Response filed Oct. 16, 2019 to Communication Pursuant to Article 94(3) EPC dated Apr. 12, 2019”, 16 pgs. |
“European Application Serial No. 9747584.2, Communication Pursuant to Article 94(3) EPC dated Feb. 20, 2017”, 7 pgs. |
“European Application Serial No. 9747584.2, Response filed Aug. 30, 2017 to Communication Pursuant to Article 94(3) EPC dated Feb. 20, 2017”, 28 pgs. |
“International Application Serial No. PCT/US2009/043966, Demand and Response filed Mar. 12, 2010 to Written Opinion dated Jul. 31, 2009”, 36 pgs. |
“International Application Serial No. PCT/US2009/043966, International Preliminary Report on Patentability dated Jul. 27, 2011”, 36 pgs. |
“International Application Serial No. PCT/US2009/043966, Search Report dated Jul. 27, 2009”, 7 pgs. |
“International Application Serial No. PCT/US2009/043966, Written Opinion dated Jul. 27, 2009”, 6 pgs. |
“International Application Serial No. PCT/US2010/057238, Response to Written Opinion filed Sep. 18, 2012”, 14 pgs. |
“International Application Serial No. PCT/US2010/057238, International Preliminary Report on Patentability dated Dec. 14, 2012”, 41 pgs. |
“International Application Serial No. PCT/US2010/057238, International Search Report dated Jan. 26, 2011”, 2 pgs. |
“International Application Serial No. PCT/US2010/057238, Written Opinion dated Jan. 26, 2011”, 9 pgs. |
“International Application Serial No. PCT/US2011/042443, International Preliminary Report on Patentability dated Jul. 31, 2012”, 29 pgs. |
“International Application Serial No. PCT/US2011/042443, International Search Report dated Nov. 25, 2011”, 2 pgs. |
“International Application Serial No. PCT/US2011/042443, Response filed Apr. 27, 2012 to Written Opinion dated Nov. 25, 2011”, 11 pgs. |
“International Application Serial No. PCT/US2011/042443, Written Opinion dated Nov. 25, 2011”, 4 pgs. |
“European Application Serial No. 16190922.1, Response filed Feb. 8, 2022 to Communication Pursuant to Article 94(3) EPC dated Jul. 29, 2021”, 16 pgs. |
“European Application Serial No. 16190922.1, Communication Pursuant to Article 94(3) EPC dated Jul. 29, 2021”, 5 pgs. |
Number | Date | Country | |
---|---|---|---|
20210078007 A1 | Mar 2021 | US |
Number | Date | Country | |
---|---|---|---|
61359636 | Jun 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16524922 | Jul 2019 | US |
Child | 16864878 | US | |
Parent | 14597677 | Jan 2015 | US |
Child | 16524922 | US | |
Parent | 13805166 | US | |
Child | 14597677 | US |